KDOAM-25, a potent and highly selective inhibitor of histone lysine demethylases 5 (KDM5) with IC50 values of 71 nM for KDM5A, 19 nM for KDM5B, 69 nM for KDM5C, and 69 nM for KDM5D, enhances global H3K4 methylation at transcriptional start sites and reduces proliferation in multiple myeloma MM1S cells.

KDM5C:69 nM , KDM5B:19 nM , KDM5D:69 nM , KDM5A:71 nM

KDOAM-25 treatment results in a G1 cell-cycle arrest with an increased proportion of MM1S in G1 and a decrease of the proportion of cells in G2 without an increase in the proportion of cells in the apoptotic sub-G1 phase. KDOAM-25 (50 μM) increases with approximately twice as much H3K4me3 in in multiple myeloma cells. KDOAM-25 inhibits most potently KDM5B with an IC50 of ～50 μM and the other KDM5 family members at concentrations above 100 μM. KDOAM-25 shows no cellular activity on any of the other tested JmjC family members. KDOAM-25 is able to reduce the viability of MM1S cells with an IC50 of ～30 μM after a delay of 5-7 days.